Show/Hide Menu

Clinical Pipeline

  • Proprietary Programs
  • Partnered Programs
  • Phase 1
  • Phase 2
  • Phase 3
  • Market
27 Antibodies available:
Program
Partner
Indication
Phase

Partner

Not partnered

Indication

Phase

Diffuse large B cell lymphoma (DLBCL, L-MIND study)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Chronic lymphocytic leukemia (CLL)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

In June 2010, MorphoSys AG and US-based biopharmaceutical company Xencor signed a worldwide exclusive license and collaboration agreement for the antibody. The agreement provided MorphoSys with an exclusive worldwide license to XmAb5574 for the treatment of cancer and other indications.

Partner

Not partnered

Indication

Phase

Multiple myeloma
Phase 1 Phase 2 (Current Phase) Phase 3 Market

In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.  Either Velcade® (bortezomib) or Revlimid® (lenalidomide) enhanced the cytotoxic activity of MOR202 in vitro and also the inhibition of MM-mediated bone lysis and tumor load in vivo. The enhancement by bortezomib was mediated through a direct cytotoxic effect on MM cells.

Lenalidomide synergistically enhanced MOR202 activity by several mechanisms identified to be direct cytotoxicity, activation of effector cells and increased CD38 expression levels on MM cells. In an orthotopic xenograft murine model of multiple myeloma, MOR202 reduced tumor load and tumor mediated bone lysis. Co-administration of MOR202 with either bortezomib or lenalidomide completely abolished bone lysis in a synergistic manner. These findings support further investigation of MOR202 combination regimens in clinical trials. MOR202 is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid Arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hand osteoarthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases, i.e. rheumatoid arthritis, where current treatment options are inadequate. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline.

Partner

Emergent BioSolutions

Indication

Phase

Metastatic, castration-resistant prostate cancer (mCRPC)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The immunotherapeutic protein activates the patients’ T-cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor.

MOR209/ES414 is part of MorphoSys’s collaboration with Emergent BioSolutions to jointly develop the compound.

Partner

Galapagos

Indication

Phase

Inflammation
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases. MOR106 arises from the alliance initiated by Galapagos and MorphoSys in 2008, in which both companies contribute their core technologies and expertise. Galapagos and MorphoSys will continue to equally share the research and development costs, as well as all future revenues.

Partner

Novartis

Indication

Phase

Sporadic inclusion body myositis (RESILIENT)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Sporadic inclusion body myositis (extension study)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Sporadic inclusion body myositis (long-term study)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Hip fracture surgery
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Cachexia (COPD)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Sarcopenia (dose-ranging)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Sarcopenia (extension study)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Partner

Roche

Indication

Phase

Mild Alzheimer's disease (Marguerite RoAD)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer´s disease
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Genetically predisposed individuals (DIAN)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
  • A fully human HuCAL antibody to treat Alzheimer‘s disease
  • Target: Amyloid-beta

Additional Information:

Partner

Janssen/J&J

Indication

Phase

Psoriasis (VOYAGE 1)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriasis (VOYAGE 2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriasis (NAVIGATE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Generalized pustular or erythrodermic psoriasis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Moderate to severe plaque-type psoriasis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Palmoplantar pustulosis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Active psoriatic arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat Psoriasis and Rheumatoid Arthritis
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

Anetumab Ravtansine

Partner

Bayer HealthCare

Indication

Phase

Mesothelioma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Mesothelin expressing lung adenocarcinoma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced malignancies (Japan)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Hepatic or renal impairment
Phase 1 (Current Phase) Phase 2 Phase 3 Market
ECG and drug interaction study
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Recurrent mesothelin-expressing platinum-resistant cancer (combo with pegylated lipsomal doxorubicin)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate to treat mesotheliomas and ovarian and pancreatic carcinomas
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

BHQ880

Partner

Novartis

Indication

Phase

Multiple myeloma (renal insufficiency)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Smoldering multiple myeloma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat osteolytic bone disease in multiple myeloma patients
  • Target: Dickkopf-1 (DKK-1)

Additional Information:

BPS804

Partner

Novartis/Mereo

Indication

Phase

Osteoporosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hypophosphatasia (HPP)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Brittle bone disease
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat bone diseases
  • Target: Sclerostin

Additional information:

CNTO3157

Partner

Janssen/J&J

Indication

Phase

Asthma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Safety / Pharmacokinetics
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat Asthma

Additional Information:

CNTO6785

Partner

Janssen/J&J

Indication

Phase

Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat Inflammatory Diseases

Additional Information:

Elgemtumab (LJM716)

Partner

Novartis

Indication

Phase

ESCC (combo with BYL719)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
HER2 + cancer (combo with BYL719 & trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
HER2 + cancer (combo with trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: HER3

Additional information:

Tarextumab

Partner

OncoMed

Indication

Phase

Small cell lung cancer (PINNACLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat pancreatic cancer and small cell lung cancer
  • Target: Notch receptor (Notch 2)
  • Alias: OMP-59R5

Additional Information:

Tesidolumab (LFG316)

Partner

Novartis

Indication

Phase

Age-related geographic atrophy
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Geographic atrophy (combo with CLG561)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Panuveitis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Paroxysmal nocturnal hemoglobinuria
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Transplant Associated Microangiopathy (TAM)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody developed in Ophthalmology 
  • Target: C5

Additional Information:

Utomilumab

Partner

Pfizer

Indication

Phase

Advanced solid tumors, combination with avelumab
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors, NHL (+rituximab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors, combination with PD-1 inhibitor MK-3475
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced solid tumors, combination with mogamulizumab
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced or metastatic carcinomas, combination with PF-04518600
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

VAY736

Partner

Novartis

Indication

Phase

Pemphigus vulgaris
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Primary Sjögren's syndrome
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid Arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat inflammatory diseases
  • Target: BAFF-R

Additional information:

BAY1093884

Partner

Bayer HealthCare

Indication

Phase

Bleeding disorders (hemophilia)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat bleeding disorders
  • Target: tissue factor pathway inhibitor (TFPI)

Additional information:

BI-836845

Partner

Boehringer Ingelheim

Indication

Phase

Solid tumors, Japanese patients
Phase 1 (Current Phase) Phase 2 Phase 3 Market
(EGFR) Mutant Non-small Cell Lung Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Breast cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Castration-resistant Prostate Cancer (CRPC) + enzalutamide
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Various solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: IGF-1

Additional Information:

NOV-7

Partner

Novartis

Indication

Phase

Eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-8

Partner

Novartis

Indication

Phase

Inflammation
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-9

Partner

Novartis

Indication

Phase

Diabetic eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-10

Partner

Novartis

Indication

Phase

Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-11

Partner

Novartis

Indication

Phase

Blood disorders
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-12

Partner

Novartis

Indication

Phase

Prevention of Thrombosis
Phase 1 (Current Phase) Phase 2 Phase 3 Market

Vantictumab

Partner

OncoMed

Indication

Phase

Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Breast cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Pancreatic cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Non-small-cell lung carcinoma
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat solid tumors
  • Target: Wnt signaling pathway (Fzd 7)
  • Alias: OMP-18R5

Additional information: